Clinical Research Directory
Browse clinical research sites, groups, and studies.
Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee
Sponsor: Addpharma Inc.
Summary
The purpose of this study is to determine the optimal dose of AD-211 in patients with osteoarthritis of the knee.
Official title: A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Determine the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee
Key Details
Gender
All
Age Range
19 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2026-06
Completion Date
2027-03
Last Updated
2026-04-24
Healthy Volunteers
No
Conditions
Interventions
AD-211-L
Per oral, 1 tablet twice daily during the treatment period.
AD-211-M
Per oral, 1 tablet twice daily during the treatment period.
AD-211-H
Per oral, 1 tablet twice daily during the treatment period.
AD-2113
Per oral, 1 tablet twice daily during the treatment period.
Placebo to AD-211-L/M
Per oral, 1 tablet twice daily during the treatment period.
Placebo to AD-211-H
Per oral, 1 tablet twice daily during the treatment period.
Placebo to AD-2113
Per oral, 1 tablet twice daily during the treatment period.